Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12200636 | 0.98 | KMT2A (0.43) | KMT2AMEN1MDM2NPC1RAB9A | |
| SCHEMBL14450381 | 0.92 | KMT2A (0.46) | KMT2AMEN1MDM2NPC1RAB9A | |
| SCHEMBL31749265 | 0.90 | KMT2A (0.54) | KMT2AMEN1MDM2NPC1RAB9A | |
| SCHEMBL27214060 | 0.90 | KMT2A (0.54) | KMT2AMEN1MDM2NPC1RAB9A | |
| SCHEMBL13379273 | 0.90 | KMT2A (0.42) | KMT2AMEN1MDM2NPC1RAB9A | |
| SCHEMBL31146900 | 0.89 | KMT2A (0.45) | KMT2AMEN1MDM2NPC1RAB9A | |
| SCHEMBL3367289 | 0.89 | KMT2A (0.45) | KMT2AMEN1MDM2NPC1RAB9A | |
| SCHEMBL29470540 | 0.89 | KMT2A (0.45) | KMT2AMEN1MDM2NPC1RAB9A | |
| SCHEMBL29368397 | 0.89 | KMT2A (0.45) | KMT2AMEN1MDM2NPC1RAB9A | |
| SCHEMBL1745934 | 0.89 | KMT2A (0.45) | KMT2AMEN1MDM2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210552-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| US-7314726-B2 | Beta secretase exosite binding peptides and methods for identifying beta secretase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-20070149763-A1 | Beta secretase exosite binding peptides and methods for identifying beta secretase modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | KMT2A 3701/4885MEN1 247/4885MDM2 3231/4885 |
| US-20100210552-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | KMT2A 3701/4885MEN1 247/4885MDM2 3231/4885 |
| US-20070149763-A1 | Beta secretase exosite binding peptides and methods for identifying beta secretase modulators | BACE1, BACE2, APP | KMT2A 4054/4885MEN1 1288/4885MDM2 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.